title: Effect of carvedilol on heart failure in patients with a functionally univentricular heart.
abstract: BACKGROUND
  The effect of carvedilol on heart failure (HF) in patients with a functionally univentricular heart (UVH) remains unclear.
  
  
  RESULTS
  Carvedilol was used to treat HF in 51 patients with a UVH, classified into 3 groups: after the Fontan operation (F), after the bidirectional Glenn operation (G), and patients who had not undergone Fontan or Glenn operation (NF). Carvedilol therapy was started at a mean age of 10 ± 12 years (range: 1 month to 34 years). The initial and maximum doses of carvedilol were 0.04 ± 0.03 and 0.42 ± 0.29 mg · kg(-1) · day(-1), respectively. After a mean follow-up of 11 months, the cardiothoracic ratio improved from 60 ± 8 to 58 ± 8% (P<0.01), and the dosage of furosemide was reduced from 1.4 ± 0.9 to 0.7 ± 0.7 mg · kg(-1) · day(-1) (P < 0.01). The ejection fraction also improved from 35 ± 12 to 40 ± 11% (P < 0.05), and this improvement was prominent in the F group (from 35 ± 15 to 45 ± 9%; P < 0.05). Clinical signs, symptoms, and New York Heart Association functional class also improved.
  
  
  CONCLUSIONS
  Carvedilol may play an important role in treating HF associated with a UVH.
authors: Department of Pediatrics, Sakakibara Heart Institute, Tokyo, Japan.
authors: Naoko
authors: N
authors: Ishibashi
authors: In-Sam
authors: IS
authors: Park
authors: Tadashi
authors: T
authors: Waragai
authors: Tadahiro
authors: T
authors: Yoshikawa
authors: Yasuo
authors: Y
authors: Murakami
authors: Katsuhiko
authors: K
authors: Mori
authors: Shigekazu
authors: S
authors: Mimori
authors: Makoto
authors: M
authors: Ando
authors: Yukihiro
authors: Y
authors: Takahashi
authors: Shouzaburo
authors: S
authors: Doi
authors: Shuuki
authors: S
authors: Mizutani
authors: Toshio
authors: T
authors: Nakanishi
mesh_terms: D000293:Adolescent; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D018729:Fontan Procedure / Q000009:adverse effects; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007223:Infant; D007564:Japan; D008297:Male; D011412:Propanolamines / Q000627:therapeutic use*; D020127:Recovery of Function; D012189:Retrospective Studies; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*; D016278:Ventricular Function, Right / Q000187:drug effects*; D055815:Young Adult
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol